• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Product › Details

DRUGS, ORPHAN

	Next higher product group	pharmaceutical

Record changed: 2021-02-05

Advertisement

More documents for DRUGS, ORPHAN

• [1] Horizon Therapeutics plc. (2/1/21). "Press Release: Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio". Dublin & Gaithersburg, MD....
• [2] Swedish Orphan Biovitrum AB. (12/21/20). "Press Release: Sobi Appoints New Head of North America Ahead of Launch Phase"....
• [3] AstraZeneca plc. (12/12/20). "Press Release: AstraZeneca to Acquire Alexion, Accelerating the Company’s Strategic and Financial Development [Not for any jurisdicition where violation of relevant laws]"....
• [4] Inflazome Ltd.. (7/14/20). "Press Release: FDA Grants Orphan Drug Designation for Inflazome’s Inzomelid for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)". Dublin, Cambridge & Brisbane....
• [5] Freeline Therapeutics Ltd.. (5/4/20). "Press Release: Freeline Receives Orphan Drug Designation from the FDA for FLT190 for the Treatment of Fabry Disease". London....
• [6] Evox Therapeutics Ltd.. (3/26/20). "Press Release: Evox Therapeutics and Takeda Sign Multi-target Rare Disease Collaboration"....
• [7] CureVac AG. (2/26/20). "Press Release: CureVac Appoints Alan Kimura, MD, PhD as Head of the Newly Created Department “Rare Diseases”". Tübingen & Boston, MA....
• [8] Audentes Therapeutics, Inc.. (12/2/19). "Press Release: Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics". Tokyo & San Francisco, CA....
• [9] Merck KGaA. (11/20/19). "Press Release: Merck Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations 8Not intended for UK-based media]". Darmstadt....
• [10] Adaptimmune Ltd.. (10/5/19). "Press Release: United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4". Philadeliphia, PA & Oxfordshire....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2021. Made in Germany.